Acapodene toremifene: Completed Phase III enrollment

GTXI completed enrollment of >1,300 patients in a 2-year, placebo-controlled, double-blind, U.S. and Mexican Phase III trial. Patients will receive either 80 mg daily Acapodene or placebo. ...